Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery

Phase 1

Terminated

Conditions: Recurrent Childhood Anaplastic Oligodendroglioma
Recurrent Childhood Anaplastic Astrocytoma
Recurrent Childhood Anaplastic Oligoastrocytoma
Recurrent Childhood Giant Cell Glioblastoma
Recurrent Childhood Glioblastoma
Recurrent Childhood Gliomatosis Cerebri
Recurrent Childhood Gliosarcoma

Interventions: Biological: oncolytic HSV-1716
Drug: dexamethasone
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis

First Posted Date: 2014-01-09

Last Posted Date: 2016-05-30

Lead Sponsor: Pediatric Brain Tumor Consortium

Target Recruit Count: 2

Registration Number: NCT02031965

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Palbociclib
Drug: Dexamethasone
Drug: Lenalidomide

First Posted Date: 2014-01-08

Last Posted Date: 2018-08-22

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 9

Registration Number: NCT02030483

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma

Phase 2

Conditions: Myeloma
Bortezomib
Cyclophosphamide
Dexamethasone
Granulocyte Colony-Stimulating Factor

Interventions: Drug: G-CSF
Drug: Bortezomib
Drug: Cyclophosphamide
Drug: Dexamethasone

First Posted Date: 2014-01-06

Last Posted Date: 2014-01-06

Lead Sponsor: Second Affiliated Hospital of Soochow University

Target Recruit Count: 60

Registration Number: NCT02027220

Locations: 🇨🇳
The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES):

Not Applicable

Terminated

Conditions: Eclampsia

Interventions: Drug: Dexamethasone

First Posted Date: 2014-01-06

Last Posted Date: 2016-05-26

Lead Sponsor: University of Mississippi Medical Center

Target Recruit Count: 1

Registration Number: NCT02027272

Locations: 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States

Sudden Hearing Loss Multi-center Clinical Trial

Not Applicable

Conditions: Full-frequency Sudden Hearing Loss

Interventions: Drug: Dexamethasone Phosphate
Drug: Ginaton

First Posted Date: 2014-01-03

Last Posted Date: 2014-01-03

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 300

Registration Number: NCT02026479

Ultrasound Guided Trigeminal Nerve Block for Typical or Atypical Facial Pain

Phase 4

Completed

Conditions: Atypical Facial Pain
Typical Facial Pain

Interventions: Drug: Bupivacaine
Drug: Dexamethasone
Drug: Triamcinolone

First Posted Date: 2013-12-31

Last Posted Date: 2017-07-11

Lead Sponsor: Northwestern University

Target Recruit Count: 60

Registration Number: NCT02024724

Locations: 🇺🇸
Anesthesiology Pain Medcine Center, Chicago, Illinois, United States

Ketamine in Post-operative Dental Pain and Recovery

Phase 3

Completed

Conditions: Post-operative Pain

Interventions: Drug: Ketamine
Drug: Normal Saline
Drug: Dexamethasone

First Posted Date: 2013-12-27

Last Posted Date: 2020-11-09

Lead Sponsor: The University of Hong Kong

Target Recruit Count: 150

Registration Number: NCT02021240

Locations: 🇭🇰
Oral and Maxillofacial Surgery, Faculty of Dentistry, The University of Hong Kong, Hong Kong, Hong Kong

Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy

Phase 2

Terminated

Conditions: Refractory Multiple Myeloma

Interventions: Drug: carfilzomib
Drug: dexamethasone
Other: laboratory biomarker analysis

First Posted Date: 2013-12-25

Last Posted Date: 2016-11-02

Lead Sponsor: Attaya Suvannasankha

Target Recruit Count: 10

Registration Number: NCT02020941

Locations: 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2013-12-13

Last Posted Date: 2016-11-01

Lead Sponsor: Celgene Corporation

Target Recruit Count: 36

Registration Number: NCT02011113

Locations: 🇯🇵
Celgene Trial Site, Tokyo, Japan

Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma in Relapse

Interventions: Drug: pomalidomide
Drug: dexamethasone
Drug: ixazomib

First Posted Date: 2013-12-09

Last Posted Date: 2023-12-01

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 118

Registration Number: NCT02004275

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸
NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States

and more 333 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy